1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
Google Scholar | Crossref | Medline2. Ryan, CJ, Smith, MR, Fizazi, K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152–160.
Google Scholar | Crossref | Medline | ISI3. Beer, TM, Armstrong, AJ, Rathkopf, DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–433.
Google Scholar | Crossref | Medline | ISI4. De Bono, JS, Oudard, S, Ozguroglu, M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154.
Google Scholar | Crossref | Medline | ISI5. Parker, C, Nilsson, D, Heinrich, S, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223.
Google Scholar | Crossref | Medline | ISI6. Berthold, DR, Pond, GR, Soban, F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242–245.
Google Scholar | Crossref | Medline | ISI7. Saylor, PJ, Smith, MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2013; 189(Suppl. 1): S34–S42; discussion S43–S44.
Google Scholar | Crossref | Medline8. Smith, MR, Finkelstein, JS, McGovern, FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.
Google Scholar | Crossref | Medline | ISI9. Conteduca, V, Di Lorenzo, G, Bozza, G, et al. Metabolic syndrome as a peculiar target for management of prostate cancer patients. Clin Genitourin Cancer 2013; 11: 211–220.
Google Scholar | Crossref | Medline10. Conteduca, V, Di Lorenzo, G, Tartarone, A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 2013; 86: 42–51.
Google Scholar | Crossref | Medline11. Grundy, SM, Brewer, HB, Cleeman, JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.
Google Scholar | Crossref | Medline | ISI12. Gacci, M, De Nunzio, C, Sebastianelli, A, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis 2017; 20: 146–155.
Google Scholar | Crossref | Medline13. Conteduca, V, Caffo, O, Derosa, L, et al. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. Prostate 2015; 75: 1329–1338.
Google Scholar | Crossref | Medline14. Conteduca, V, Caffo, O, Galli, L, et al. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol 2018; 36: 240.e1–240.e11.
Google Scholar | Crossref | Medline15. Bassett, WW, Cooperberg, MR, Sadetsky, N, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 2005; 66: 1060–1065.
Google Scholar | Crossref | Medline16. Basaria, S, Lieb, J, Tang, AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779–786.
Google Scholar | Crossref | Medline | ISI17. Braga-Basaria, M, Dobs, AS, Muller, DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979–3983.
Google Scholar | Crossref | Medline18. Smith, MR, Lee, H, Nathan, DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305–1308.
Google Scholar | Crossref | Medline | ISI19. Lu-Yao, G, Nikita, N, Keith, SW, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020; 77: 158–166.
Google Scholar | Crossref | Medline20. Faris, JE, Smith, MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010; 17: 240–246.
Google Scholar | Crossref | Medline21. Saylor, PJ, Smith, MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998–2008.
Google Scholar | Crossref | Medline | ISI22. Pollak, M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915–928.
Google Scholar | Crossref | Medline | ISI23. Smith, JC, Bennett, S, Evans, LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261–4267.
Google Scholar | Crossref | Medline | ISI24. Karantanos, T, Karanika, S, Gignac, G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer 2016; 23: 691–698.
Google Scholar | Crossref | Medline25. Nobes, JP, Langley, SEM, Klopper, T, et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012; 109: 1495–1502.
Google Scholar | Crossref | Medline26. de Velasco, G, Lora, D, Lorente, D, et al. Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials. J Clin Oncol 2018; 36(Suppl. 6): 230.
Google Scholar | Crossref27. Wu, J, Yu, E. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer Metastasis Rev 2014; 33: 607–617.
Google Scholar | Crossref | Medline28. Kobayashi, T, Kamba, T, Terada, N, et al. High incidence of urological complications in men dying from prostate cancer. Int J Clin Oncol 2016; 21: 1150–1154.
Google Scholar | Crossref | Medline29. Won, ACM, Gurney, H, Marx, G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 2013; 112: E250–E255.
Google Scholar | Crossref | Medline30. Culp, SH, Schellhammer, PF, Williams, MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014; 65: 1058–1066.
Google Scholar | Crossref | Medline | ISI31. Armstrong, AJ, Lin, P, Higano, CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol 2018; 29: 2200–2207.
Google Scholar | Crossref | Medline32. Scher, HI, Halabi, S, Tannock, I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–1159.
Google Scholar | Crossref | Medline | ISI33. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
Google Scholar | Crossref | Medline | ISI34. Flanagan, J, Gray, PK, Hahn, N, et al. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 2011; 22: 801–807.
Google Scholar | Crossref | Medline | ISI35. Gong, Z, Agalliu, I, Lin, DW, et al. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192–1202.
Google Scholar | Crossref | Medline | ISI36. Amling, CL, Riffenburgh, RH, Sun, L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439–445.
Google Scholar | Crossref | Medline | ISI37. Harshman, LC, Werner, L, Tripathi, A, et al. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate 2017; 77: 1303–1311.
Google Scholar | Crossref | Medline38. Jung, J, Lee, C, Lee, C, et al. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean J Urol 2015; 56: 630–636.
Google Scholar | Crossref | Medline39. Lorente, D, De Velasco Oria, GA, Carles, J, et al. Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial. Ann Oncol 2018; 29(Suppl. 8): VIII279–VIII280.
Google Scholar | Crossref | Medline